Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PR4 + ledipasvir + sofosbuvir + simeprevir
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination regimen consisting of four agents: PR4 (identity not established in the provided sources), ledipasvir, sofosbuvir, and simeprevir. Ledipasvir is an HCV NS5A inhibitor; sofosbuvir is an HCV NS5B nucleotide polymerase inhibitor; and simeprevir is an HCV NS3/4A protease inhibitor. These direct-acting antivirals are used in various combinations for the treatment of chronic hepatitis C virus (HCV) infection. The triple combination of ledipasvir, sofosbuvir, and simeprevir has been studied for its efficacy in achieving sustained virologic response in patients with HCV genotype 1 infection[3][6][7]. However, coadministration of all three drugs can result in significant pharmacokinetic interactions that increase drug concentrations and potential adverse effects; thus this specific combination is generally not recommended without careful clinical oversight[3][4]. The role or identity of "PR4" as a pharmaceutical agent could not be confirmed from available data.
- Brand names
- Harvoni (for ledipasvir/sofosbuvir)Olysio (for simeprevir)
02
Targets
NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on PR4 + ledipasvir + sofosbuvir + simeprevir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PR4 + ledipasvir + sofosbuvir + simeprevir.